PharmaBoardroom

Interview with Andrew Carter, Managing Director, Commercial Eyes

What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian…

Interview with Ralf Dahmen, Managing Director, Galderma

As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role…

Interview with Richard Davies, Managing Director, Amgen Australia

What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They…

Interview with Will Delaat, Chairman, Pharmaceutical Industry…

2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an…

Interview with George Varkanis, Managing Director, Celgene

As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a…

Interview with Di Ford, Executive Director, Generic Medicines…

To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are:…

Interview with Mark Glover , Vice President and Managing…

How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well…

Interview with Alek Safarian , Managing Director, Novotech…

One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s…

Interview with Rob Botha, Vice President UTI Pharma Africa, UTI…

We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are…

Interview with Troy Guthrie, Managing Director, Stiefel…

What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although…

Interview with Hans-Dieter Hausner, Senior Bayer Representative,…

Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect?…

Interview with Suzanne Hill, Chair, Pharmaceutical Benefits…

To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the…

Tagged with